Pelthos Therapeutics Reports 17% Q1 Revenue Growth on ZELSUVMI Momentum
Event summary
- ZELSUVMI net product revenue grew 17% quarter-over-quarter to $10.7 million in Q1 2026.
- Units dispensed increased 25% to 7,884, with 3,228 unique prescribers.
- Pelthos expanded its sales force by 14 representatives, reaching 64 territory managers.
- Secured a $50 million term loan facility from Horizon Technology Finance, drawing $30 million at close.
- Cash balance as of March 31, 2026, was $32 million, expected to support current business plan.
The big picture
Pelthos Therapeutics is building momentum with its lead product, ZELSUVMI, which addresses a highly contagious viral skin infection primarily affecting children. The company's strategic expansion of its sales force and securing a significant term loan position it to accelerate commercialization efforts. The broader biopharmaceutical industry is witnessing increased focus on innovative treatments for unmet patient needs, and Pelthos' ability to execute on its business plan will be critical in maintaining its competitive edge.
What we're watching
- Commercial Momentum
- Whether Pelthos can sustain the 25% quarter-over-quarter growth in ZELSUVMI units dispensed.
- Product Pipeline
- The pace at which Pelthos advances the commercialization of XEPI and XEGLYZE in 2027.
- Financial Flexibility
- How the $50 million term loan will be utilized to strengthen the balance sheet and accelerate commercialization.
Related topics